2257 Stock Overview
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People’s Republic of China, and Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Sirnaomics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.36 |
| 52 Week High | HK$59.00 |
| 52 Week Low | HK$5.64 |
| Beta | -0.55 |
| 1 Month Change | -9.14% |
| 3 Month Change | -75.91% |
| 1 Year Change | -85.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2257 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.7% | 4.7% | 1.7% |
| 1Y | -85.7% | -33.4% | -7.1% |
Return vs Industry: 2257 underperformed the Hong Kong Biotechs industry which returned -33.4% over the past year.
Return vs Market: 2257 underperformed the Hong Kong Market which returned -7.1% over the past year.
Price Volatility
| 2257 volatility | |
|---|---|
| 2257 Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2257's share price has been volatile over the past 3 months.
Volatility Over Time: 2257's weekly volatility has increased from 10% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 145 | Alan Patrick Lu | www.sirnaomics.com |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People’s Republic of China, and Hong Kong. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat remodeling. The company’s lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis.
Sirnaomics Ltd. Fundamentals Summary
| 2257 fundamental statistics | |
|---|---|
| Market cap | HK$638.96m |
| Earnings (TTM) | -HK$615.03m |
| Revenue (TTM) | HK$3.10m |
205.9x
P/S Ratio-1.0x
P/E RatioIs 2257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2257 income statement (TTM) | |
|---|---|
| Revenue | US$397.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$397.00k |
| Other Expenses | US$79.09m |
| Earnings | -US$78.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -19,821.41% |
| Debt/Equity Ratio | 125.3% |
How did 2257 perform over the long term?
See historical performance and comparison